{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:59:59Z","timestamp":1772467199205,"version":"3.50.1"},"reference-count":33,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"Abstract<\/jats:title>\nOBJECTIVE<\/jats:bold> To determine the effectiveness of metronomic cyclophosphamide (MC) chemotherapy (primary treatment of interest) with adjuvant meloxicam administration as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy.<\/jats:p>\nDESIGN<\/jats:bold> Retrospective case series with nested cohort study.<\/jats:p>\nANIMALS<\/jats:bold> 39 dogs with a histologic diagnosis of appendicular osteosarcoma that underwent limb amputation and completed carboplatin chemotherapy from January 2011 through December 2015.<\/jats:p>\nPROCEDURES<\/jats:bold> Dogs were grouped by whether carboplatin chemotherapy had been followed with or without MC chemotherapy (15 mg\/m2<\/jats:sup>, PO, q 24 h) and meloxicam (0.1 mg\/kg [0.045 mg\/lb], PO, q 24 h). The Breslow rank test was used to assess whether MC chemotherapy was associated with overall survival time (OST) and disease progression-free time (PFT) after limb amputation.<\/jats:p>\nRESULTS<\/jats:bold> 19 dogs received carboplatin and MC chemotherapy, and 20 dogs received only carboplatin chemotherapy. No differences were identified between these groups regarding age, reproductive status, body weight, serum alkaline phosphatase activity, tumor location, or histologic grade or subtype of osteosarcoma. Median duration of MC chemotherapy for dogs in the carboplatin-MC group was 94 days (range, 7 to 586 days); this treatment was discontinued for 11 (58%) dogs when cystitis developed. Overall, 11 (28%) dogs survived to the time of analysis, for a median follow-up period of 450 days (range, 204 to 1,400 days). No difference in median PFT or OST was identified between the 2 groups.<\/jats:p>\nCONCLUSIONS AND CLINICAL RELEVANCE<\/jats:bold> Maintenance MC chemotherapy following limb amputation and completed carboplatin chemotherapy was associated with no increase in PFT or OST in dogs with appendicular osteosarcoma. Cystitis was common in MC-treated dogs, and prophylactic treatment such as furosemide administration could be considered to reduce the incidence of cystitis in such dogs.<\/jats:p>","DOI":"10.2460\/javma.252.11.1377","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T03:23:14Z","timestamp":1526613794000},"page":"1377-1383","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy"],"prefix":"10.2460","volume":"252","author":[{"given":"Arata","family":"Matsuyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney R.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Paul","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Am Vet Med Assoc","first-page":"995","article-title":"Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978\u20131988)","volume":"200","author":"Spodnick","year":"1992"},{"key":"ref2","series-title":"J Vet Intern Med","first-page":"177","article-title":"Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin","volume":"2","author":"Mauldin","year":"1988"},{"key":"ref3","series-title":"J Am Vet Med Assoc","first-page":"531","article-title":"Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979\u20131990)","volume":"200","author":"Thompson","year":"1992"},{"key":"ref4","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1939-1676.1996.tb02031.x","article-title":"Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)","volume":"10","author":"Bergman","year":"1996"},{"key":"ref5","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1939-1676.2003.tb02434.x","article-title":"Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog","volume":"17","author":"Bailey","year":"2003"},{"key":"ref6","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"382","DOI":"10.5326\/0410382","article-title":"Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma","volume":"41","author":"Chun","year":"2005"},{"key":"ref7","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5326\/0450033","article-title":"Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs","volume":"45","author":"Phillips","year":"2009"},{"key":"ref8","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/vco.12069","article-title":"Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial","volume":"14","author":"Skorupski","year":"2016"},{"key":"ref9","series-title":"Nat Rev Clin Oncol","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010"},{"key":"ref10","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2407-9-81","article-title":"Characterization of STAT3 activation and expression in canine and human osteosarcoma","volume":"9","author":"Fossey","year":"2009"},{"key":"ref11","series-title":"In Vivo","first-page":"15","article-title":"Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours","volume":"18","author":"Wergin","year":"2004"},{"key":"ref12","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1476-5829.2007.00153.x","article-title":"Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma","volume":"6","author":"Thamm","year":"2008"},{"key":"ref13","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1939-1676.2010.0557.x","article-title":"Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma","volume":"24","author":"Biller","year":"2010"},{"key":"ref14","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1939-1676.2011.0753.x","article-title":"Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma","volume":"25","author":"Burton","year":"2011"},{"key":"ref15","series-title":"Acta Pharmacol Sin","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/aps.2010.97","article-title":"Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy","volume":"31","author":"Zhu","year":"2010"},{"key":"ref16","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"960","DOI":"10.18632\/oncotarget.358","article-title":"Pilot study of a pediatric metronomic 4-drug regimen","volume":"2","author":"Andr\u00e9","year":"2011"},{"key":"ref17","series-title":"J Transl Med","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-014-0225-y","article-title":"High dose lansoprazole combined with metronomic chemotherapy: a phase I\/II study in companion animals with spontaneously occurring tumors","volume":"12","author":"Spugnini","year":"2014"},{"key":"ref18","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1476-5829.2011.00280.x","article-title":"Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer","volume":"10","author":"Leach","year":"2012"},{"key":"ref19","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/jsap.12228","article-title":"Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma","volume":"55","author":"Bracha","year":"2014"},{"key":"ref20","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/vco.12179","article-title":"Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs","volume":"15","author":"Rasmussen","year":"2017"},{"key":"ref21","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e0124889","DOI":"10.1371\/journal.pone.0124889","article-title":"Impact of toceranib\/piroxicam\/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: a multi-institutional study","volume":"10","author":"London","year":"2015"},{"key":"ref22","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana","year":"2007"},{"key":"ref23","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1939-1676.2008.0179.x","article-title":"Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas","volume":"22","author":"Elmslie","year":"2008"},{"key":"ref24","series-title":"Invest New Drugs","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10637-011-9672-y","article-title":"First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study","volume":"30","author":"Marchetti","year":"2012"},{"key":"ref25","series-title":"Vet Comp Oncol","first-page":"417","article-title":"Veterinary Cooperative Oncology Group: common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016"},{"key":"ref26","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1354\/vp.39-2-240","article-title":"Prognostic significance of a new histologic grading system for canine osteosarcoma","volume":"39","author":"Kirpensteijn","year":"2002"},{"key":"ref27","series-title":"Biochem Pharmacol","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/0006-2952(79)90222-3","article-title":"Cyclophosphamide cystitis: identification of acrolein as the causative agent","volume":"28","author":"Cox","year":"1979"},{"key":"ref28","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2460\/javma.2003.222.1388","article-title":"Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990\u20131996)","volume":"222","author":"Charney","year":"2003"},{"key":"ref29","series-title":"Vet Rec","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/vr.101574","article-title":"Mesna and furosemide for prevention of cyclophosphamide-induced sterile haemorrhagic cystitis in dogs: a retrospective study","volume":"174","author":"Laberke","year":"2014"},{"key":"ref30","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jvim.12313","article-title":"Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma","volume":"28","author":"Selmic","year":"2014"},{"key":"ref31","series-title":"J Am Vet Med Assoc","first-page":"1002","article-title":"Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990\u20131996)","volume":"213","author":"Ehrhart","year":"1998"},{"key":"ref32","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1939-1676.2000.tb02281.x","article-title":"Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma","volume":"14","author":"Garzotto","year":"2000"},{"key":"ref33","series-title":"BMC Vet Res","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1746-6148-8-56","article-title":"Prognostic factors in canine appendicular osteosarcoma: a meta-analysis","volume":"8","author":"Boerman","year":"2012"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/252\/11\/javma.252.11.1377.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/252\/11\/javma.252.11.1377.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/252\/11\/javma.252.11.1377.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:57:56Z","timestamp":1741348676000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/252\/11\/javma.252.11.1377.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":33,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.252.11.1377","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}